(VIANEWS) – Shares of Castle Biosciences (NASDAQ: CSTL) slid 9.02% to $22.09 at 13:58 EST on Tuesday, following the last session’s downward trend. NASDAQ is sliding 0.72% to $11,591.72, following the last session’s downward trend. This seems, as yet, a somewhat down trend trading session today.
Castle Biosciences’s last close was $24.28, 49.83% below its 52-week high of $48.40.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-1.24.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.86%.
Yearly Top and Bottom Value
Castle Biosciences’s stock is valued at $22.09 at 13:58 EST, way under its 52-week high of $48.40 and way above its 52-week low of $15.58.
Volatility
Castle Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.00%, a negative 0.32%, and a positive 2.68%.
Castle Biosciences’s highest amplitude of average volatility was 4.90% (last week), 2.62% (last month), and 2.68% (last quarter).
Volume
Today’s last reported volume for Castle Biosciences is 78536 which is 49.32% below its average volume of 154981.
More news about Castle Biosciences (CSTL).
